Analysis of Plasma Homocysteine Levels in Patients with Chronic Periodontitis Before and After Nonsurgical Periodontal Therapy Using High-Performance Liquid Chromatography

Abstract

Introduction: Homocysteine (Hcy), an inflammatory biomarker, is a sulfur-containing amino acid. Elevated levels of plasma Hcy are evident in various inflammatory conditions and have been described as an independent risk factor for cardiovascular disease. The literature has also stated that a similar association could exist between the chronic periodontitis and plasma-Hcy levels, in otherwise systemically healthy individuals. However, studies on Hcy levels in periodontitis are scarce. Hence, this study aimed to assess the levels of plasma Hcy in patients with chronic periodontitis before and after nonsurgical periodontal therapy. Materials and Methods: This longitudinal, case–control clinical study included a total of 60 patients who were divided into two groups. Periodontal parameters including Plaque Index, Gingival Index, Sulcus Bleeding Index, probing depth, and clinical attachment level were recorded at baseline and 12 weeks after periodontal therapy. A high-performance liquid chromatography analysis was performed to measure the Hcy levels. The results were evaluated statistically for intergroup pair-wise comparisons by Mann–Whitney U-test and intragroup comparison by Wilcoxon-matched pairs test. Correlation between the plasma-Hcy levels with other clinical parameters in all groups was done by Spearman’s rank correlation method. Results: The Hcy was detectable in all the samples. At baseline, the mean levels of plasma Hcy were found to be low in the control group, whereas in the test group, it is found to be higher. These plasma-Hcy levels and all periodontal parameters were reduced significantly after nonsurgical periodontal therapy. Conclusion: The results demonstrated that plasma-Hcy levels are reduced after nonsurgical periodontal therapy but not to the levels comparable with those found in healthy individuals. Therefore, nonsurgical periodontal therapy may be used as an adjunctive Hcy-lowering therapy, contributing toward primary prevention against cardiovascular diseases.

Keywords: Biological markers, cardiovascular disease, inflammation

Introduction

Periodontal disease is a chronic inflammatory infectious disease affecting the supporting tissues of teeth including gingiva, periodontal ligament, cementum, and alveolar bone.[1] Periodontitis, which is a constant potential source of infection,[2] has been considered as a separate risk factor for diabetes, cardiovascular diseases, cerebrovascular diseases, respiratory diseases, and low birthweight rheumatoid arthritis through common pathophysiological pathways.[3,4] Cardiovascular disease is the single leading cause of morbidity and mortality globally as per the World Health Organization statistics,[3] wherein < 50% of the patients with atherosclerosis lack identifiable risk factors. As evidence documented that individuals with periodontitis have a greater risk of presenting endothelial dysfunction and cardiovascular diseases, the pathogenesis of periodontal disease and atherosclerotic disease can hence be related through common inflammatory cascades.[5]

Despite the various inflammatory mediators elevated in cardiovascular events, namely, intercellular adhesion molecule, IL-6, TNF-α, IL-8, and CRP,[6,7] homocysteine (Hcy), an inflammatory biomarker, was also evidenced in patients with cardiovascular diseases.[9]

Hcy, a sulfur-containing amino acid, which in the recent past has become a biomolecule of great importance for biochemists and clinicians alike. Hcy

Access this article online

Website: www.contempclindent.org
DOI: 10.4103/ccd.ccd_650_18

How to cite this article: Penmetsa GS, Bhaskar RU, Mopidevi A. Analysis of plasma homocysteine levels in patients with chronic periodontitis before and after nonsurgical periodontal therapy using high-performance liquid chromatography. Contemp Clin Dent 2020;11:266-73.
is exported into plasma where it circulates, mostly in its oxidized form, bound to plasma proteins as a protein-Hcy mixed disulfide with albumin (protein-SS-Hcy).[10] Under normal circumstances, most but not all of the Hcy formed in transmethylation reactions is remethylated back to methionine or is converted into cysteine in transsulfuration reactions. The B-complex vitamins play an essential role in the transformation and the excretion of the Hcy metabolism pathway,[11] the elevated levels of Hcy that is, hyper-Hcy (HHcy) has been associated with pathologic alteration in the vasculature, which is recognized as an independent cardiovascular disease risk factor.[11-13] The literature evidence also shows that a rise in plasma-Hcy concentration beyond 15 μmol (5–15 μmol) is a risk factor for cardiovascular disease.[14]

Not only this inflammatory biomarker associated with cardiovascular disease, but it has also been investigated in patients with rheumatoid arthritis, wherein the immunoinflammatory activation of rheumatoid arthritis contributes to the Hcy increase.[7]

It is evident from the literature that nonsurgical periodontal therapy decreases inflammatory cytokine levels in chronic periodontitis patients,[15] and hence it may be considered that by improving periodontal health, local and systemic inflammation can be reduced, which in turn reduces the complications associated with these conditions.

Taking these aspects into consideration, it was hypothesized that periodontal intervention therapy might reduce the systemic inflammatory burden, which in turn could act as a Hcy-lowering therapy and serve a dual purpose in not only managing the periodontal disease but also in the management of other chronic inflammatory conditions. Hence, an attempt has been made in this study to analyze the Hcy levels in chronic periodontitis patients before and after nonsurgical periodontal therapy.

**Materials and Methods**

This 3-month follow-up case-control study included a total of 60 patients, of which 30 patients who were diagnosed with chronic periodontitis[16] were allocated to test group and 30 patients with healthy periodontium were allocated to the control group. The study protocol was reviewed and approved by the Institutional Review Board and Ethical Committee of Vishnu Dental College, Andhra Pradesh. Written informed consent was obtained from all the participants after thorough explanation of the nature of risks and benefits of the clinical investigation and associated procedures. The sample size was calculated based on a pilot study with a standard deviation value of Hcy levels 8.27 μmol/l, and the difference between the two groups with 6 μmol/l with a confidence level of 95% and a statistical power of 80%. Patients diagnosed with systemic and infectious diseases, patients on any medications from the past 6 months, smokers, and pregnant women were excluded from the study.

**Criteria for inclusion of periodontally healthy individuals (Group A):**

- Age range of 25–65 years
- A minimum of 20 teeth in the mouth
- Patients diagnosed with moderate-to-severe periodontitis according to American Academy of Periodontology guidelines of 1999
- The presence of at least four sites in different teeth with clinical attachment loss ≥3 mm (moderate-to-severe periodontitis)
- Patients who had not received periodontal treatment in the past 1 year.

The primary end-point of the study was to assess plasma-Hcy levels and the secondary end-point was to assess periodontal parameters, namely, Plaque Index,[17] Gingival Index,[18] Sulcular Bleeding Index,[19] probing depth, and clinical attachment level before and after the nonsurgical periodontal therapy (NSPT). The parameters were assessed at baseline and at 3 months from the baseline visit. At the initial visit, blood sample was collected and periodontal parameters were assessed, followed by NSPT and at 3 months from the baseline visit again periodontal parameters were assessed and the blood sample collection was performed to assess Hcy levels. After NSPT, oral hygiene instructions were given to each patient.

**Methodology**

Patients were advised to come after an overnight fasting for the blood sample collection before scaling and root planning, wherein a 5 ml of venous blood was collected through venipuncture from the median cubital vein and at 3 months from the baseline visit. These blood samples were transferred to a test tube containing ethylenediaminetetraacetic acid anticoagulant. The blood samples were centrifuged at 3500 rpm for 10 min to extract the plasma, and this plasma was immediately transferred to a plastic veil and stored at −20°C until Hcy analysis was carried out with high-performance liquid chromatography method HPLC equipment, waters india pvt Ltd. bangtore, India, and the column used for HPLC, Inertsil ODS C18 of size 4.6 mm × 250 mm, 5 μm, detector used was dual λ absorption spectrometer.

**Sample preparation**

All the samples were assayed for Hcy using HPLC with dual λ absorption spectrometer, and the assay protocol as proposed by Shaik.[20]
Homocysteine levels in chronic periodontitis patients before and after NSPT

Homocysteine (Hcy) is derived from the amino acid methionine and regulated by the folate and vitamin B12 pathways. It is a potent risk factor for cardiovascular disease (CVD), as it influences the endothelial function. Abnormalities in Hcy metabolism are associated with various cardiovascular diseases, such as cardiovascular disease, diabetes mellitus, and rheumatoid arthritis. Considering the above findings associated with periodontal disease, recent research has focused on the objective measures to predict any association between the periodontitis and other systemic diseases. Among the innumerable biomarkers that have been evidenced in the periodontal literature, Hcy is one among them.

Hcy is an inflammatory biomarker which is considered as a potent risk factor for cardiovascular disease. As hyperhomocysteinemia IE elevated levels of Hcy can induce damage to vascular walls either directly through the protein homocysteinylation (Hcyn) or through an oxidative

**Statistical analysis**

Data analysis was performed using statistical software SPSS 20.0 IBM corporation. Chicago Stata 8.0. statacorp Medcalc 9.0.1. medcalc software Systat 120. sylstat software Inc, CA, USA. The data were described using mean and standard deviation. Mann–Whitney U-test was used for intergroup comparisons and Wilcoxon-matched pairs test for intragroup comparison. The correlation between the plasma-Hcy levels with other clinical parameters in all groups was done by Spearman’s rank correlation method.

P < 0.05 was considered to be statistically significant for all analyses.

**Results**

The study included a total of 30 chronic periodontitis patients comprising of 12 male and 18 female patients and 30 patients who are periodontally healthy individuals comprising of 19 males and 11 female patients were recruited in the study [Table 1]. The mean age standard deviation in test and control groups are SD 45.53±7.64. SD 41.57±6.3 years respectively which is depicted in Table 2. Intragroup comparisons of PI, GI, BI, PD and mean CAL are depicted in Tables 3-7 which are statistically significant. Inter group comparisons between test and control with mean preoperative mean PI, mean GI, mean PD, and mean CAL are depicted in Tables 8-12 respectively wherein, there is a statistically significant difference between test and control groups. There is statistically significant decrease in PD before and after treatment [Tables 13 and 14]. On the other hand, Hcy levels for test group (26.39±9.01 μmol/l) and control group (14.05±1.98μmol/l) showed significant difference which is depicted in Table 15. Also a significant statistical difference in decrease in probing depths before and after treatment were depicted in Table 16. The preoperative and post-operative correlations amongst the different parameters of PI, GI, BI, PD, CAL and Hcy levels are presented in Tables 17 and 18.

**Discussion**

Periodontal disease is initiated by bacterial-plaque biofilm attached to tooth surfaces, resulting in damage to the supporting structures comprising of gingiva, periodontal ligament, cementum, and alveolar bone. Along with the biofilm, products of periodontal pathogens consisting of enzymes, toxins, and lipopolysaccharides induce an inflammatory response in the host. Furthermore, an uncontrolled, overexuberant inflammatory response in chronic periodontitis associated with an oxidative stress-induced inflammatory pathogenesis, has been linked with systemic diseases such as cardiovascular disease, diabetes mellitus, and rheumatoid arthritis.[2-3] Considering the above findings associated with periodontal disease, recent research has focused on the objective measures such as biomarkers to assess the current disease status and also to predict any association between the periodontitis and other systemic diseases. Among the innumerable biomarkers that have been evidenced in the periodontal literature, Hcy is one among them.

**Table 1: Distribution of male and females in the study groups (test and control)**

| Sex     | Test group (%) | Control group (%) | Total |
|---------|----------------|-------------------|-------|
| Male    | 12 (40.00)     | 19 (63.33)        | 31    |
| Female  | 18 (60.00)     | 11 (36.67)        | 29    |
| Total   | 30 (100.00)    | 30 (100.00)       | 60    |

**Table 2: Comparison of two study groups (test and control) with mean age by t-test**

| Groups       | Mean±SD  |
|--------------|----------|
| Test group   | 45.53±7.64 |
| Control group| 41.57±6.93 |
| Total        | 42.89±7.34 |
| t            | 0.7472    |
| P            | 0.4579    |

SD: Standard deviation
stress response Hcy may cause protein functional damage by inactivation of the enzyme lysyl oxidase,\cite{21} which is required for collagen modification and this HHcy has been recognized as a risk factor for cardiovascular diseases. In HHcy, Hcy proteins accumulate in the vascular wall surfaces which are recognized by the macrophages, leading to the phagocytosis and the destruction of the endothelial cells. If the responsible agent (homocysteination proteins) is present continually on endothelial cells, it would eventually lead to atherosclerotic plaque formation. This atherosclerotic plaque formation also enhances the pro-oxidant activity and nitric oxide expression, ultimately changing the endothelial cell phenotype from anticoagulant to procoagulant;\cite{22} other probable mechanisms that promote atherosclerotic action of Hcy are molecular target hypothesis and endoplasmic stress hypothesis, and it may also be assumed that periodontal tissue damage may accelerate specific remethylation reactions of DNA, RNA, and various proteins during tissue repair, with consequent generation of S-adenosyl Hcy and release of Hcy, a mechanism which is similar to that seen in autoimmune conditions, such as rheumatoid arthritis. These mechanisms suggest the pathways through which inflammatory processes in chronic periodontitis influence the plasma-Hcy concentrations. It was also hypothesized that the periodontal inflammatory cascade can affect the methionine metabolism leading to HHcy.

Hcy can be detected in a variety of different laboratory techniques, which include chromatography, electrophoresis, and immunoassay. In immunoassay laboratory technique, the commonly used are enzyme-linked immunosorbent assay (ELISA), chemiluminescent, and fluorescent detection. However, the use of HPLC with dual λ detector was opted over ELISA for the detection and estimation of Hcy, as the former shows higher sensitivity and wider range over the latter. The HPLC protocol validated in a study\cite{23} has been employed in the present study to evaluate the plasma-Hcy concentration in chronic periodontitis before and after NSPT.

### Table 3: Comparison of pre- and post-operative Plaque Index scores in test group by Wilcoxon matched pairs test

| Time        | Mean±SD  | Mean difference | SD difference | Percentage of change | Z       | P      |
|-------------|----------|-----------------|---------------|----------------------|---------|--------|
| Preoperative| 1.64±0.43| 0.92            | 0.38          | 56.32                | 4.6225  | 0.001* |
| Postoperative| 0.72±0.32|                |               |                      |         |        |

*P<0.05. SD: Standard deviation

### Table 4: Comparison of pre- and post-operative Gingival Index scores in test group by Wilcoxon matched pairs test

| Time        | Mean±SD  | Mean difference | SD difference | Percentage of change | Z       | P      |
|-------------|----------|-----------------|---------------|----------------------|---------|--------|
| Preoperative| 1.48±0.40| 0.95            | 0.42          | 64.44                | 4.5771  | 0.0001*|

*P<0.05. SD: Standard deviation

### Table 5: Comparison of pre- and post-operative Bleeding Index scores in test group by paired t-test

| Time        | Mean±SD  | Mean difference | SD difference | Percentage of change | Z       | P      |
|-------------|----------|-----------------|---------------|----------------------|---------|--------|
| Preoperative| 67.28±17.20| 39.66          | 18.15         | 58.95                | 11.5615 | 0.0001*|
| Postoperative| 27.62±15.84|               |               |                      |         |        |

*P<0.05. SD: Standard deviation

### Table 6: Comparison of pre- and post-operative probing depth scores in test group by paired t-test

| Time        | Mean±SD  | Mean difference | SD difference | Percentage of change | Z       | P      |
|-------------|----------|-----------------|---------------|----------------------|---------|--------|
| Preoperative| 4.09±0.88| 1.22            | 0.90          | 29.87                | 7.1909  | 0.0001*|
| Postoperative| 2.87±0.61|                |               |                      |         |        |

*P<0.05. SD: Standard deviation

### Table 7: Comparison of pre- and post-operative clinical attachment level scores in test group by Paired t-test

| Time        | Mean±SD  | Mean difference | SD difference | Percentage of change | Z       | P      |
|-------------|----------|-----------------|---------------|----------------------|---------|--------|
| Preoperative| 4.65±1.27| 1.04            | 1.13          | 22.42                | 4.8589  | 0.0001*|
| Postoperative| 3.60±0.92|                |               |                      |         |        |

*P<0.05. SD: Standard deviation

### Table 8: Comparison of study groups (test and control) with preoperative mean Plaque Index scores by Mann-Whitney U-test

| Group       | n  | Mean±SD  | Mean rank | U       | Z       | P      |
|-------------|----|----------|-----------|---------|---------|--------|
| Test group  | 30 | 1.65±0.43| 45.50     | 0.00    | -6.6530 | 0.0001*|
| Control group| 30| 0.26±0.10| 15.50     |         |         |        |

*P<0.05. SD: Standard deviation

Penmetsa, et al.: Homocysteine levels in chronic periodontitis patients before and after NSPT
As per the literature available, it can be considered that if the inflammatory states were really implicated in the genesis of hyperhomocysteinuria, a decrease in plasma-Hcy concentration could be expected following periodontal therapy, owing to the reduction of systemic inflammatory load.\[^{[15]}\] Moreover, a study suggested that plasma-Hcy levels above 14 μmol/l\[^{[24]}\] warrant a treatment to decelerate the growth of carotid plaque formation. Nonsurgical periodontal therapy belongs to the first phase of periodontal treatment, wherein the primary objective is to completely remove the gingival inflammation provoking elements (i.e., plaque, calculus, and endotoxins) from the tooth surface, thereby helping in improving the host defense by restoring the disturbed oxidant:antioxidant balance. Restoration of this oxidant:antioxidant balance may help to delay or control the onset of various systemic inflammatory diseases, at least those initiated by periodontitis.\[^{[25]}\] Hence, an attempt was made to evaluate the efficacy of nonsurgical periodontal therapy on plasma-Hcy levels in chronic periodontitis patients.

The results of the present study indicated a rise in the plasma Hcy concentrations in test group (preoperative 26.67 ± 8.77 μmol/L) when compared to the control group (14.05 ± 1.98 μmol/L). The results obtained are in conjunction with the previous studies which demonstrated elevated plasma Hcy concentrations using ELISA in similarly defined chronic periodontitis subjects over the controls.\[^{[6,26]}\] On the contrary, Hcy concentrations in chronic periodontitis patients have been reported in the studies using chemiluminescent immunoassay.\[^{[27,28]}\]

The elevated plasma Hcy in our test group may be a consequence of the persistent immunoinflammatory activation by periodontal pathogens. There could be several possible mechanisms underlying the link between chronic periodontitis and plasma-Hcy. Pro-inflammatory cytokines, such as IL-6, which may be released from inflamed periodontal pockets and may give rise to acute-phase reactants in the systemic circulation. McCarty\[^{[29]}\] has reported that IL-6 may interact with Vitamin B6 metabolism and compromise cystathionine β-synthase activity, thereby elevating plasma-Hcy concentrations. This suggests that hyperhomocysteinuria could be expected by the release of IL-6 from the inflamed pocket walls of the periodontal tissues.\[^{[29]}\]

On the other hand, a significant reduction of plasma-Hcy levels in postoperative test group to 19.87 ± 6.44 μmol/l was evident after 12 weeks of NSPT. This reduction of plasma-Hcy levels connotes the reinstitution of the Hcy–methionine homeostasis which may be attributable to the presumed reduction in the serum IL-6 and reactive oxygen metabolites.

This finding is in an agreement with a previous study demonstrating elevation in Hcy concentrations with incrementing severity of periodontal disease.\[^{[6]}\] These observations reinforce the hypothesis that plasma-Hcy concentration is positively correlated with increasing periodontal destruction and that it is lowering partly depends on the residual pocket depth and clinical attachment level after periodontal therapy.
Table 13: Comparison of pre- and post-operative probing depth with 3-5 mm scores in test group by paired t-test

| Time          | Mean±SD   | Mean difference | SD difference | Percentage of change | Z       | P       |
|---------------|-----------|-----------------|---------------|----------------------|---------|---------|
| Preoperative  | 51.89±16.04 | 28.00           | 19.07         | 53.96                | 7.7698  | 0.0001* |
| Postoperative | 23.89±14.83 |                 |               |                      |         |         |

*P<0.05. SD: Standard deviation

Table 14: Comparison of pre- and post-operative probing depth with >5 mm scores in test group by paired t-test

| Time          | Mean±SD   | Mean difference | SD difference | Percentage of change | Z       | P       |
|---------------|-----------|-----------------|---------------|----------------------|---------|---------|
| Preoperative  | 11.54±13.71 | 7.43            | 9.68          | 64.40                | 4.0617  | 0.0004* |
| Postoperative | 4.11±5.96  |                 |               |                      |         |         |

*P<0.05. SD: Standard deviation

Table 15: Comparison of study groups (test and control) with preoperative mean homocysteine level scores by Independent t-test

| Group     | n   | Mean±SD       | SE  | t       | P       |
|-----------|-----|---------------|-----|---------|---------|
| Test group| 30  | 26.67±8.77    | 1.60| 7.6891  | 0.0001* |
| Control group | 30 | 14.05±1.98    | 0.36|         |         |

*P<0.05. SD: Standard deviation; SE: Standard error

Table 16: Comparison of pre- and post-operative homocysteine level scores in test group by Paired t-test

| Time          | Mean±SD | Mean difference | SD difference | Percentage of change | Z       | P       |
|---------------|---------|-----------------|---------------|----------------------|---------|---------|
| Preoperative  | 26.39±9.01 | 6.52            | 4.61          | 24.69                | 7.4735  | 0.0001* |
| Postoperative | 19.87±6.44 |                 |               |                      |         |         |

*P<0.05. SD: Standard deviation

Table 17: Correlations among different preoperative parameters by Karl Pearson’s correlation coefficient

| Variables | Summary | PI  | GI  | BI  | PD   | CAL  | Homocysteine level |
|-----------|---------|-----|-----|-----|------|------|--------------------|
| PI        | r       | -   |     |     |      |      |                    |
|           | p       |     |     |     |      |      |                    |
| GI        | r       | 0.749** | -   |     |      |      |                    |
|           | p       | 0.0000 |     | -   |      |      |                    |
| BI        | r       | 0.777** | 0.834** | - |      |      |                    |
|           | p       | 0.0001 | 0.0001 |  | -    |      |                    |
| PD        | r       | 0.2740 | 0.2770 | 0.3660 | -    |      |                    |
|           | p       | 0.1590 | 0.1540 | 0.0550 | -    |      |                    |
| CAL       | r       | 0.391* | 0.3250 | 0.432* | 0.913** | - |      |
|           | p       | 0.0400 | 0.0910 | 0.0220 | 0.0001 | - |      |
| Homocysteine level | r       | 0.0520 | 0.1350 | 0.2190 | 0.1460 | 0.0860 | - |
|           | p       | 0.7950 | 0.4920 | 0.2630 | 0.4600 | 0.6640 | - |

**Correlation is significant at the 0.01 level (two-tailed). *Correlation is significant at the 0.05 level (two-tailed). PI: Plaque Index; GI: Gingival Index; BI: Bleeding Index; PD: Probing depth; CAL: Clinical attachment level

Hence, within the limitations of the study, it can be summarized that with an increase in periodontal inflammation, there is a substantial rise in the concentration of Hcy in plasma. The interventional therapy, including scaling and root planning reduces the periodontal inflammation and Hcy levels, which in turn could reduce the risk of cardiovascular diseases.

**Limitations of the study**

As the main enzyme involved in the metabolism of Hcy requires the presence of cofactors such as Vitamin B_6_ and B_12_, the deficiencies of these vitamins are also associated with elevated levels of Hcy in various pathological conditions. Therefore, it is important that the levels of these B vitamins need to be elucidated to provide a better representation of the inflammatory conditions.

Hence, further studies can be performed with a large sample size and an assay of Vitamin B_6_, B_12_, and IL-6 need to be included to provide a holistic picture of role of Hcy in periodontal disease.
Table 18: Correlations among different postoperative parameters by Karl Pearson’s correlation coefficient

| Variables          | Summary | PI      | GI      | BI      | PD      | CAL     | Homocysteine level |
|--------------------|---------|---------|---------|---------|---------|---------|-------------------|
| PL                 | $r$     | -       | -       | -       | -       | -       | -                 |
| $P$                |         |         |         |         |         |         |                   |
| GI                 | $r$     | 0.875** | -       | -       | -       | -       | -                 |
| $P$                |         | 0.0001  |         |         |         |         |                   |
| BI                 | $r$     | 0.528** | 0.605** | -       | -       | -       | -                 |
| $P$                |         | 0.0040  | 0.0010  |         |         |         |                   |
| PD                 | $r$     | 0.1460  | 0.1980  | 0.474*  | -       | -       | -                 |
| $P$                |         | 0.4580  | 0.3130  | 0.0110  |         |         |                   |
| CAL                | $r$     | 0.1010  | 0.0310  | 0.0570  | 0.609** | -       | -                 |
| $P$                |         | 0.6080  | 0.8770  | 0.7730  | 0.0010  |         |                   |
| Homocysteine level | $r$     | 0.0700  | 0.0450  | 0.437*  | 0.3630  | 0.3460  | -                 |
| $P$                |         | 0.7220  | 0.8200  | 0.0200  | 0.0570  | 0.0710  |                   |

**Correlation is significant at the 0.01 level (two-tailed), *Correlation is significant at the 0.05 level (two-tailed). PI: Plaque Index; GI: Gingival Index; BI: Bleeding Index; PD: Probing depth; CAL: Clinical attachment level

Conclusion

The results of the present study showed that the plasma-Hcy levels were found to be elevated in patients with chronic periodontitis as compared to patients with healthy periodontal status. These levels reduced significantly following nonsurgical periodontal therapy, but not to the levels evident in periodontally healthy individuals. One of the various benefits of nonsurgical periodontal therapy is the reduction of Hcy levels which may contribute toward prevention of cardiovascular diseases. However, this needs to be evaluated further in longitudinal studies with larger sample size.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Armitage GC. Periodontal diseases: Diagnosis. Ann Periodontol 1996;1:37-215.
2. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E, et al. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001;72:1221-7.
3. Van Dyke TE, Serhan CN. Resolution of inflammation: A new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82:82-90.
4. Prabhu A, Michalowicz BS, Mathur A. Detection of local and systemic cytokines in adult periodontitis. J Periodontol 1996;67:515-22.
5. World Health Organization. Programmes and Projects. Fact Sheet No_317: Cardiovascular Diseases (CVDs). Geneva: World Health Organization; 2009.
6. Joseph R, Nath SG, Joseraj MG. Elevated plasma homocysteine levels in chronic periodontitis: A hospital-based case-control study. J Periodontol 2011;82:439-44.
7. Wällberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantanpää-Dahlfqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol 2002;29:875-82.
8. Lopez-Olivo MA, Gonzalez-Lopez L, Garcia-Gonzalez A, Villa-Manzano AI, Cota-Sanchez AR, Salazar-Paramo M, et al. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 2006;35:112-6.
9. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-22.
10. Andersson A, Isaksson A, Hultberg B. Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 1992;38:1311-5.
11. Debreceni B, Debreceni L. The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease. Cardiovasc Ther 2014;32:130-8.
12. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1999;50:31-62.
13. Bautista LE, Arenas IA, Peñuela A, Martínez LX. Total plasma homocysteine level and risk of cardiovascular disease: A meta-analysis of prospective cohort studies. J Clin Epidemiol 2002;55:882-7.
14. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: A meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9.
15. D’Aiuto F, Nibali M. Short-term effects of intensive periodontal therapy on serum inflammatory markers and cholesterol. Clin Pharmacol Ther 1987;34:489-95.
16. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
17. Loe H. The gingival index, the plaque index and the retention index systems. J Periodontol 1967;38:610-6.
18. Loe H. The gingival index, the plaque index and the retention index systems. J Periodontol 1967;38:Suppl: 610-6.
19. Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J 1975;25:229-35.
20. Shaik MM, Gan SH. Rapid resolution liquid chromatography method development and validation for simultaneous determination of homocysteine, Vitamins B(6), B(9), and B(12) in human serum. Indian J Pharmacol 2013;45:159-67.
21. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 1997;272:32370-7.
22. Upchurch GR Jr., Welch GN, Fabian AJ, Freedman JE,
Johnson JL, Keaney JF Jr., et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.

23. Ducros V, Demuth K, Sauvant MP, Quillard M, Caussé E, Candito M, et al. Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B Analyt Technol Biomed Life Sci 2002;781:207-26.

24. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 micromol/L. Am J Hypertens 2000;13:105-10.

25. George AK, Janam P. The short-term effects of non-surgical periodontal therapy on the circulating levels of interleukin-6 and C-reactive protein in patients with chronic periodontitis. J Indian Soc Periodontol 2013;17:36-41.

26. Agnihotram G, Singh MT, Pamidimarri G, Jacob L, Rani S. Study of clinical parameters in chronic periodontitis. J Periodontol 2010;54:1202-8.

27. Han DH, Shin HS, Kim MS, Paek D, Kim HD. Group of serum inflammatory markers and periodontitis-metabolic syndrome coexistence in Koreans. J Periodontol 2012;83:612-20.

28. Chapple IL, Milward MR, Dietrich T. The prevalence of inflammatory periodontitis is negatively associated with serum antioxidant concentrations. J Nutr 2007;137:657-64.

29. McCarty MF. Increased homocyst(e)ine associated with smoking, chronic inflammation, and aging may reflect acute-phase induction of pyridoxal phosphatase activity. Med Hypotheses 2000;55:289-93.